No connection

Search Results

ATRA vs NMTC

ATRA
Atara Biotherapeutics, Inc.
BEARISH
Price
$5.22
Market Cap
$37.6M
Sector
Healthcare
AI Confidence
85%
NMTC
NeuroOne Medical Technologies Corporation
BEARISH
Price
$0.73
Market Cap
$37.0M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ATRA
1.83
NMTC
--
Forward P/E
ATRA
11.66
NMTC
-2.61
P/B Ratio
ATRA
-1.03
NMTC
5.75
P/S Ratio
ATRA
0.25
NMTC
3.16
EV/EBITDA
ATRA
0.91
NMTC
-4.55

Profitability

Gross Margin
ATRA
46.76%
NMTC
22.03%
Operating Margin
ATRA
-102.72%
NMTC
-59.02%
Profit Margin
ATRA
15.4%
NMTC
-58.28%
ROE
ATRA
--
NMTC
-146.27%
ROA
ATRA
30.86%
NMTC
-63.4%

Growth

Revenue Growth
ATRA
-91.4%
NMTC
-11.7%
Earnings Growth
ATRA
--
NMTC
--

Financial Health

Debt/Equity
ATRA
--
NMTC
0.04
Current Ratio
ATRA
1.02
NMTC
6.41
Quick Ratio
ATRA
0.86
NMTC
4.95

Dividends

Dividend Yield
ATRA
--
NMTC
--
Payout Ratio
ATRA
0.0%
NMTC
0.0%

AI Verdict

ATRA BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and financial distress. Despite a current price of $5.22 appearing low relative to an intrinsic value estimate of $20.02, the company exhibits alarming fundamentals including negative operating margin (-102.72%), collapsing revenue (YoY growth: -91.40%), and a bearish insider selling trend. While recent earnings surprises have been positive, the long-term financial instability, lack of reliable Altman Z-Score, and deteriorating cash position overshadow any valuation appeal. The stock's technical trend is deeply bearish, and analyst consensus is only a 'hold' with limited coverage, further undermining confidence.

Strengths
Recent quarterly earnings have consistently beaten estimates, with an average surprise of +242% over the last four quarters
Gross margin remains relatively strong at 46.76%, suggesting some pricing power or cost control in core operations
Current price of $5.22 is significantly below the growth-based intrinsic value estimate of $20.02, implying potential upside if fundamentals stabilize
Risks
Piotroski F-Score of 2/9 indicates very weak financial health, with red flags across profitability, leverage, and operating efficiency
Operating margin of -102.72% reflects unsustainable cost structure and lack of path to profitability
Revenue has collapsed by 91.4% year-over-year, signaling severe commercial or operational challenges
NMTC BEARISH

NMTC presents a contradictory profile with a stable Piotroski F-Score of 6/9 and a very strong liquidity position (Current Ratio 6.41), yet it suffers from severe operational decay. The company is experiencing negative revenue growth (-11.70% YoY) and deep losses, evidenced by an ROE of -146.27%. While the balance sheet is clean with minimal debt (D/E 0.04), the bearish technical trend and consistent lack of profitability make it a high-risk speculative play.

Strengths
Very low Debt/Equity ratio (0.04)
Strong short-term liquidity (Current Ratio 6.41)
Stable Piotroski F-Score (6/9) indicating some internal financial improvements
Risks
Negative revenue growth (-11.70% YoY and -11.65% Q/Q)
Severe negative profit margins (-58.28%)
High Price-to-Book ratio (5.75) relative to lack of earnings

Compare Another Pair

ATRA vs NMTC: Head-to-Head Comparison

This page compares Atara Biotherapeutics, Inc. (ATRA) and NeuroOne Medical Technologies Corporation (NMTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile